Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPLET in Advanced Cholangiocarcinoma
NCT05823311Phase 3Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of lenvatinib, tislelizumab in cholangiocarcinoma (CCA), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Sep 2023; status: recruiting.
02
Drugs
lenvatinibtislelizumab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05823311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05823311.